These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.
Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Eli Lilly faces allegations it ran a "multi-tiered kickback scheme" to pump up sales of key diabetes drugs.
In the ongoing saga of Outcome Health, a judge yesterday denied a request by investors to freeze part of its funding.
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.
AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.
Armed with a new cardiovascular benefit nod, Novo Nordisk’s diabetes fighter Victoza has a better shot at fighting off newer rivals.